Decheng Capital is a prominent venture capital firm specializing in early and growth-stage investments within the healthcare and life sciences sectors. With over $440 million in capital under management, Decheng Capital focuses on companies with revolutionary technologies and strong market presence. Their typical investment rounds include Series A, B, and C, reflecting their commitment to nurturing companies through critical growth phases.
Notable portfolio companies include Aadi Bioscience, Adela, Alpine Immune Sciences, and Arcus Biosciences, among others. Decheng Capital's investment philosophy emphasizes strategic support and capital infusion to help build legendary companies. The firm offers unique value-add services such as deep industry expertise and a robust network to accelerate the growth of their portfolio companies. Key partners and decision-makers at Decheng bring extensive experience from leading institutions in the life sciences sector.
Decheng Capital - Portfolio Snapshot
Portfolio activity breakdown across disclosed investments and stages